Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi

被引：28
作者：
Baudi, Ian [1 ,2 ]
Inoue, Takako [3 ]
Tanaka, Yasuhito [1 ,2 ,3 ]
机构：
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi 4678601, Japan
[2] Nagoya City Univ, Grad Sch Med Sci, Liver Unit, Nagoya, Aichi 4678601, Japan
[3] Nagoya City Univ Hosp, Dept Clin Lab Med, Nagoya, Aichi 4678602, Japan
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 03期
关键词：
chronic hepatitis B (CHB); liver fibrosis; hepatocellular carcinoma (HCC); cirrhosis; intrahepatic covalently closed circular DNA (cccDNA); hepatitis B core-related antigen (HBcrAg); Wisteria floribunda agglutinin-positive Mac-2 binding protein; MAC-2; BINDING-PROTEIN; CORE-RELATED ANTIGEN; NUCLEOS(T)IDE ANALOG THERAPY; SURFACE-ANTIGEN; LIVER FIBROSIS; GLYCOSYLATION ISOMER; VIRUS DNA; ENZYME-IMMUNOASSAY; MAC-2-BINDING PROTEIN; HBV;
D O I：
10.3390/ijms21030949
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The hepatitis B virus (HBV) cannot be removed completely from infected hepatocytes, owing to the presence of intrahepatic covalently closed circular DNA (cccDNA). As chronic hepatitis B (CHB) can progress to cirrhosis and hepatocellular carcinoma (HCC), predicting HCC development in high-risk patients with high viral replicative activity or advanced fibrosis is important. Novel serological biomarkers reflect intrahepatic viral replicative activity or the progression of liver fibrosis, indicating non-invasive alternatives to liver biopsy: (1) Hepatitis B core-related antigen (HBcrAg) correlates with serum HBV DNA and intrahepatic cccDNA. In CHB patients, a decrease in HBcrAg is associated with favorable outcomes. HBcrAg can predict HCC occurrence or recurrence. (2) Measurement of the Mac-2 binding protein glycosylation isomer (M2BPGi) has been introduced for the evaluation of liver fibrosis. An increase in M2BPGi in CHB patients is related to the progression of liver fibrosis and high potential (risk) of HCC development. Here, we describe the clinical applications of HBcrAg and M2BPGi in CHB patients. Additionally, because new potential therapeutic agents that eliminate intrahepatic cccDNA are being developed, monitoring of HBcrAg or M2BPGi might be suitable for evaluating therapeutic effects and the clinical outcomes. In conclusion, these would be appropriate surrogate markers for predicting disease progression.
引用
收藏
页数：19
相关论文
共 93 条
[1]   Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease [J].
Abe, Masanori ;
Miyake, Teruki ;
Kuno, Atsushi ;
Imai, Yasuharu ;
Sawai, Yoshiyuki ;
Hino, Keisuke ;
Hara, Yuichi ;
Hige, Shuhei ;
Sakamoto, Michiie ;
Yamada, Gotaro ;
Kage, Masayoshi ;
Korenaga, Masaaki ;
Hiasa, Yoichi ;
Mizokami, Masashi ;
Narimatsu, Hisashi .
JOURNAL OF GASTROENTEROLOGY, 2015, 50 (07) :776-784
[2]   JS']JSH Guidelines for the Management of Hepatitis B Virus Infection [J].
Asahina, Yasuhiro ;
Hayashi, Norio ;
Hiramatsu, Naoki ;
Izumi, Namiki ;
Koike, Kazuhiko ;
Kumada, Hiromitsu ;
Kurosaki, Masayuki ;
Oketani, Makoto ;
Suzuki, Fumitaka ;
Takikawa, Hajime ;
Tanaka, Atsushi ;
Tanaka, Eiji ;
Tanaka, Yasuhito ;
Tsubouchi, Hirohito ;
Yotsuyanagi, Hiroshi .
HEPATOLOGY RESEARCH, 2014, 44 :1-58
[3]   Sampling variability of liver fibrosis in chronic hepatitis C [J].
Bedossa, P ;
Dargère, D ;
Paradis, V .
HEPATOLOGY, 2003, 38 (06) :1449-1457
[4]   Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review [J].
Bellan, Mattia ;
Castello, Luigi Mario ;
Pirisi, Mario .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2018, 6 (03) :317-325
[5]   Current concepts: Liver biopsy. [J].
Bravo, AA ;
Sheth, SG ;
Chopra, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :495-500
[6]   Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up [J].
Brouwer, Willem P. ;
Chan, Henry Lik-Yuen ;
Brunetto, Maurizia R. ;
Martinot-Peignoux, Michelle ;
Arends, Pauline ;
Cornberg, Markus ;
Cherubini, Beatrice ;
Thompson, Alex J. V. ;
Liaw, Yun-Fan ;
Marcellin, Patrick ;
Janssen, Harry L. A. ;
Hansen, Bettina E. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) :1481-+
[7]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[8]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[9]   Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death [J].
Chen, Jin-De ;
Yang, Hwai-I ;
Iloeje, Uchenna H. ;
You, San-Lin ;
Lu, Sheng-Nan ;
Wang, Li-Yu ;
Su, Jun ;
Sun, Chien-An ;
Liaw, Yun-Fan ;
Chen, Chien-Jen .
GASTROENTEROLOGY, 2010, 138 (05) :1747-U38
[10]   Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients [J].
Chen, Shipeng ;
Jia, Jian'an ;
Gao, Yuzhen ;
Li, Huiming ;
Fang, Meng ;
Feng, Huijuan ;
Guan, Wenqian ;
Ji, Jun ;
Gao, Zhiyuan ;
Gao, Chunfang .
CLINICA CHIMICA ACTA, 2018, 486 :237-244
12345678910